Recent Updates
Recently added Catalysts
XTNT Positive Sentiment

Xtant Medical Highlights Growing Product Portfolio at NASS 2023

Thursday, October 12, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xtant Medical Holdings, Inc. is set to exhibit its expanding range of orthobiologics and spinal fixation products at NASS 2023. The company emphasizes its commitment to providing advanced surgical solutions for spinal disorders. This event marks a significant opportunity for Xtant to showcase its innovations in the medical technology sector.
Price reaction · baseline $1.09 (2023-10-12 close) · hit after-hours · clean, no other XTNT news in the window
day 0 close
-0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Xtant Medical is showcasing a growing product portfolio.
  • The company focuses on innovative surgical solutions.
  • Participation in NASS 2023 highlights industry engagement.

Full Press Release Details

BELGRADE, Mont. , Oct. 12, 2023 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it will exhibit its suite of orthobiologics and spinal fixation products

Frequently Asked Questions

What products is Xtant Medical showcasing at NASS 2023?

Xtant Medical is exhibiting its suite of orthobiologics and spinal fixation products.

What is the focus of Xtant Medical?

Xtant Medical focuses on surgical solutions for the treatment of spinal disorders.

Where is NASS 2023 taking place?

NASS 2023 is a significant event for the medical technology industry.

ShareAdd on Google
Tags: XTNT Viatris Investor Conferences Healthcare Xtant Medical spinal disorders orthobiologics NASS 2023 medical technology
Last updated: Oct 12, 2023

Biotech snapshot

Cash runway
$10M liquidity · $2M/mo burn
~4 mo
High dilution risk